It depends when the last of the patients begin to be treated. The treatment goes on for 12 months before unblinding and first analysis. Both trials are big and it will take some time to enrol all the patients. Then collating and analysis will take a few weeks or even a couple of months as everything will need to be checked for completeness and consistency. So I don't see it being any earlier than 2023.
Ann: Opthea Finalizes Ph 3 Study Designs and Startup Activities, page-18
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
82.5¢ |
Change
0.015(1.85%) |
Mkt cap ! $1.015B | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 84.5¢ | 80.0¢ | $2.835M | 3.473M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17359 | 82.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 83.0¢ | 106026 | 2 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |